LEAF 4L6715
Alternative Names: LEAF-4L6715; Liposomal Transcrocetin - LEAF4Life; Liposomal Transcrocetin relatedLatest Information Update: 07 Feb 2025
At a glance
- Originator LEAF4Life
- Class Antineoplastics; Carotenoids; Dicarboxylic acids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
- Mechanism of Action Oxygen compound modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Adult respiratory distress syndrome
Most Recent Events
- 11 Oct 2024 LEAF4Life plans a phase III trial for Adult respiratory distress syndrome in France (IV) in November 2024 (NCT06640777)
- 24 Aug 2021 LEAF4Life completes a phase-I/II clinical trials in Adult respiratory distress syndrome in France (IV) (NCT04378920) (EUDRACT2020001393–30)
- 24 Jun 2021 Efficacy and adverse events data from a phase-I/II clinical trials in Adult respiratory distress syndrome released by LEAF4Life